Aromatase Inhibition as a Treatment for Endometriosis and Breast Cancer

Alyssa Tipler
Dr. Cassidy Dobson, Faculty Mentor

Aromatase is a key enzyme in the biosynthesis of estrogen and has been shown to be overexpressed in both endometrial and breast cancer tissues. Both endometrial and breast cancer tissue have shown to be estrogen-dependent. Since aromatase is responsible for the overproduction of estrogen, disrupting aromatase activity may lead to new and effective drugs. Currently, there are three aromatase inhibitors on the market (anastrozole, exemestane, and letrozole) but each has a list of unwanted side effects. We have identified a potent aromatase inhibitor that may have the potential to inhibit the activity of aromatase. In order to measure the potency of this inhibitor, a colorimetric aromatase activity assay will be conducted in order to look at aromatase activity in the presence of competitive aromatase inhibitors. 

 

Keywords: Aromatase, Estrogen, Breast Cancer, Endometriosis , Aromatase inhibitors

Topic(s):Biochemistry and Molecular Biology
Biology

Presentation Type: Poster

Session: TBA
Location: TBA
Time: TBA